JPRN-jRCT2080225225已完成2 期
A Phase II, long-term, extension study of DS-5141b in Patients With Duchenne Muscular Dystrophy
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 5age old 至 ot applicable（—）
- 性别
- Male
入选标准
- •Has competed a study of DS5141-A-J101.
排除标准
- •1) Significant safety issues in a study of DS5141-A-J101
- •2) Patient who does not consent to use appropriate contraception
- •3) Patient who was judged by the investigator that is not appropriate to participate in this study
研究者
相似试验
进行中（未招募）
2 期
Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular DystrophyDuchenne Muscular DystrophyNCT04433234Daiichi Sankyo Co., Ltd.8
已完成
2 期
A Phase I/IIb extension study assessing the long-term safety and efficacy of an adeno-associated viral vector containing a codon-optimized human factor IX gene (AAV5-hFIX) previously administered to adult patients with severe or moderately severe haemophilia B during the CT-AMT-060-01 Phase I/II study.Christmas disease1006447710005330NL-OMON54158CSL Behring LLC6
进行中（未招募）
1 期
A Phase I/IIb extension study assessing the long-term safety and efficacy of a gene therapy (AAV5-hFIX) previously administered to adult patients with severe or moderately severe haemophilia B during the CT-AMT-060-01 Phase I/II study.Haemophilia BMedDRA version: 20.0Level: LLTClassification code 10018939Term: Haemophilia B (Factor IX)System Organ Class: 100000004850EUCTR2020-000739-28-DKuniQure biopharma B.V.10
招募中
1 期
A Phase I/IIb extension study assessing the long-term safety and efficacy of a gene therapy (AAV5-hFIX) previously administered to adult patients with severe or moderately severe haemophilia B during the CT-AMT-060-01 Phase I/II study.Haemophilia BMedDRA version: 20.0Level: LLTClassification code: 10018939Term: Haemophilia B (Factor IX) Class: 10010331CTIS2024-512603-39-00CSL Behring LLC9
招募中
2 期
A Phase I/IIb extension study assessing the long-term safety and efficacy of a gene therapy (AAV5-hFIX) previously administered to adult patients with severe or moderately severe haemophilia B during the CT-AMT-060-01 Phase I/II study.2024-512603-39-00CSL Behring LLC9